Last reviewed · How we verify

NCT04125667

Culture System for Isolating Circulating Tumor cells_2

Status unknown Last updated 14 October 2019
What this trial tests

trial in Early Diagnosis in 45 participants. Status unknown.

Timeline
31 October 2019
Primary endpoint
31 August 2020
31 August 2020

Quick facts

Lead sponsorNational Taiwan University Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment45
Start date31 October 2019
Primary completion31 August 2020
Estimated completion31 August 2020
Sites1 location across Taiwan

Conditions studied

Sponsor

National Taiwan University Hospital

Who can join

Adults 20 to 70, any sex, with Early Diagnosis or Diagnostic Techniques and Procedures. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This culture system utilizes the special affinity difference of biomedical material coating for different cells to achieve the effect of isolating tumor cells from the blood sample. The coating of the system has the characteristic that to make the WBCs adhesion, but the cancer cells in the blood sample suspend in the culture medium, which achieves the effect of separating cancer cells from the blood. The supernatant with the cancer cells can further be isolated from the cultural system for related analysis and detection to achieve early diagnosis and screening.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other National Taiwan University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04125667.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing